| Product Unit Size | Cost | Quantity | Stock |
|---|
RGW-611 is a morpholine derivative. It is a structural isomer of nimorazole, both of which are nitroimidazoles. RGW-611 may be present as an impurity in production of nimorazole. Nimorazole is a radiosensitizer with anticancer and anti-parasitic activities.
| Cas No. | 6497-78-5 |
|---|---|
| Purity | ≥98% |
| Formula | C9H14N4O3 |
| Formula Wt. | 226.24 |
| Chemical Name | 4-(2-(4-Nitro-1H-imidazol-1-yl)ethyl)morpholine |
| IUPAC Name | 4-[2-(4-Nitro-1H-imidazol-1-yl)ethyl]morpholine |
| Solubility | 10 mM in DMSO |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.
Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.
Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.
Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.